Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A paper by Oxford BRC-supported researchers says that linking research funding to Athena SWAN gender equality action plans has been associated with a rise in the number of women in mid-level leadership positions and the proportion of funding going to women.

Female scientist in the lab © Medical Sciences Division and John Cairns

The paper, published in the BMJ, said that more funders should trial funding incentives as they have been shown to work. The research team was led by Pavel Ovseiko, Senior Research Fellow in the Radcliffe Department of Medicine.

To accelerate women’s advancement and leadership, the National Institute for Health Research (NIHR) in 2011 linked its research funding to the implementation by universities of gender equality action plans through the Athena SWAN (Scientific Women’s Academic Network) charter.

In the 2016 round of the competition, the NIHR said it would not shortlist any research centre where the academic partners had not achieved at least the Athena SWAN silver award.

After the introduction of the Athena SWAN incentives, the proportion of female theme leads in BRCs increased from 8%in both 2006 and 2011 to 24% in 2016. The proportion of women in senior director positions also increased, albeit more modestly, from 11% in 2006 and 10% in 2011 to 15% in 2016.

The full story is available on the NIHR Oxford Biomedical Research Centre website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.